A phase III, prospective, multicentre, open label, extension study, to assess the long term safety and efficacy of repeated treatment of Dysport intramuscular injection in the treatment of lower limb spasticity in adult subjects with spastic hemiparesis due to stroke or traumatic brain injury

Trial Profile

A phase III, prospective, multicentre, open label, extension study, to assess the long term safety and efficacy of repeated treatment of Dysport intramuscular injection in the treatment of lower limb spasticity in adult subjects with spastic hemiparesis due to stroke or traumatic brain injury

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Apr 2018

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Muscle spasticity
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Ipsen
  • Most Recent Events

    • 27 Apr 2018 Results from NCT01249404 and the extension study NCT01251367, presented at the 70th Annual Meeting of the American Academy of Neurology
    • 23 Apr 2018 According to an Ipsen Biopharmaceuticals media release, data from this study will be presented at the American Academy of Neurology (AAN) 2018.
    • 23 Apr 2018 Results presented in an Ipsen Biopharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top